MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Venture Capital: Risk Capital_Angel, Venture, Sovereign Wealth Investor Companies & Organizations
*Venture Capital Companies: Life Science, Health IT & Healthcare Investors
Vector Fund-TEDCO
Atritech
Parents
*Architects: Neurology, Psychology, Mental Health, CNS, Pain & TBI Companies _ Stroke
*Architects: Surgical Technology _ Cardiovascular, Cardiac & Cardiology Companies
*Industry: Minnesota
Boston Scientific:Acquisitions
Companies: Acquired_(M&A)
Finance & Acquisition: Thoma Bravo
Finance & Acquisitions: Boston Scientific
Portfolio Companies: Tullis
Prism VentureWorks
Rahn Group
Split Rock Partners
Vector Fund-TEDCO
Children
*Portfolio Companies: Sightline
$22.5 million round (2006)
2011: Boston Scientific to Acquire Artitech for up to $275 million (2011)
ATRITECH COMPLETES $30 MILLION FINANCING (2009)
Developed Proprietary Technology Focused on Replacing Long Term Anticoagulation Therapy for Patients with Non-valvular Atrial Fibrillation at Risk of Stroke.
Founded 2008
Has developed proprietary technology focused on replacing long term anticoagulation therapy for patients with non-valvular atrial fibrillation at risk of stroke.
Minneapolis, Minnesota
Over the past 3 years, the Company has raised approximately $75 million in capital (2009)
Plymouth, Minnesota
Prism Venture Partners
Proprietary technology focused on replacing long term anticoagulation therapy for patients with non-valvular atrial fibrillation at risk of stroke.
Stroke prevention procedure
The company has conducted a large randomized clinical trial comparing the WATCHMAN® Left Atrial Appendage Closure Technology to long term Warfarin therapy in patients with non-valvular atrial fibrillation at risk of stroke
WATCHMAN® Left Atrial Appendage Closure Technology